|
[1] SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J].CA Cancer J Clin, 2014, 64(1):9-29.
|
|
[2] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
|
|
[3] SIEGEL RL, MILLER KD, JEMAL A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30.
|
|
[4] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
|
[5] CHEN W, SUN K, ZHENG R, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1):1-12.
|
|
[6] KORC M, CHANDRASEKAR B, YAMANAKA Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha[J]. J Clin Invest, 1992, 90(4):1352-1360.
|
|
[7] YAMANAKA Y, FRIESS H, KOBRIN MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness[J]. Anticancer Res, 1993, 13(3):565-569.
|
|
[8] YAMAOKA T, OHBA M, OHMORI T. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms[J]. Int J Mol Sci, 2017, 18(11):e2420.
|
|
[9] CATALDO VD, GIBBONS DL, PÉREZ-SOLER R, et al. Treatment of non-small-cel lung cancer with erlotinib or gefitinib[J]. N Engl J Med, 2011, 364(10):947-955.
|
|
[10] CITRI A, YARDEN Y. EGF-ERBB signalling:Towards the systems level[J]. Nat Rev Mol Cel Biol, 2006, 7(7):505-516.
|
|
[11] BALABAN EP, MANGU PB, KHORANA AA, et al. Locally advanced, unresectable pancreatic cancer:American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol,2016, 34(22):2654-2668.
|
|
[12] SOHAL DP, MANGU PB, KHORANA AA, et al. Metastatic pancreatic cancer:American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2016, 34(23):2784-2796.
|
|
[13] Pancreatic Cancer Committee of Chinese Anti-Cancer Association. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer(2018 version)[J]. J Clin Hepatol,2018, 34(10):2109-2120.(in Chinese）中国抗癌协会胰腺癌专业委员会．胰腺癌综合诊治指南（2018版）[J]．临床肝胆病杂志，2018, 34(10):2109-2120.
|
|
[14] TIERNEY JF, STEWART LA, GHERSI D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007, 8:16.
|
|
[15] MOORE MJ, GOLDSTEIN D, HAMM J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:A phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15):1960-1966.
|
|
[16] CASCINU S, BERARDI R, LABIANCA R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer:A randomised, multicentre, phase II trial[J]. Lancet Oncol, 2008, 9(1):39-44.
|
|
[17] PHILIP PA, BENEDETTI J, CORLESS CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma:Southwest Oncology Group-directed intergroup trial S0205[J]. J Clin Oncol, 2010, 28(22):3605-3610.
|
|
[18] PROPPER D, DAVIDENKO I, BRIDGEWATER J, et al. Phase II, randomized, biomarker identification trial(MARK)for erlotinib in patients with advanced pancreatic carcinoma[J]. Ann Oncol, 2014, 25(7):1384-1390.
|
|
[19] WANG JP, WU CY, YEH YC, et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations:A randomized, open-label, prospective trial[J]. Oncotarget,2015, 6(20):18162-18173.
|
|
[20] BURTNESS B, POWELL M, CATALANO P, et al. Randomized phaseⅡtrial of irinotecan/docetaxel or irinotecan/docetaxel plus cetuximab for metastatic pancreatic cancer:An Eastern Cooperative Oncology Group Study[J]. Am J Clin Oncol,2016, 39(4):340-345.
|
|
[21] HAMMEL P, HUGUET F, van LAETHEM JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4months of gemcitabine with or without erlotinib:The LAP07randomized clinical trial[J]. JAMA, 2016, 315(17):1844-1853.
|
|
[22] SCHULTHEIS B, REUTER D, EBERT MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer:A multicenter, randomized phase IIb study[J]. Ann Oncol, 2017, 28(10):2429-2435.
|
|
[23] HARTWIG W, WERNER J, JÄGER D, et al. Improvement of surgical results for pancreatic cancer[J]. Lancet Oncol,2013, 14(11):e476-e485.
|
|
[24] JIN KZ, HUANG QY, LIU C, et al. New advances in diagnosis and treatment of pancreatic cancer[J]. Chin J Dig Surg,2019, 18(7):657-661.(in Chinese）金凯舟，黄秋依，刘辰，等．胰腺癌诊断与治疗的新进展[J]．中华消化外科杂志，2019, 18(7):657-661.
|
|
[25] GILLEN S, SCHUSTER T, MEYER ZUM BÜSCHENFELDE C,et al. Preoperative/neoadjuvant therapy in pancreatic cancer:A systematic review and meta-analysis of response and resection percentages[J]. PLoS Med, 2010, 7(4):e1000267.
|
|
[26] KAMISAWA T, ISAWA T, KOIKE M, et al. Hematogenous metastases of pancreatic ductal carcinoma[J]. Pancreas, 1995,11(4):345-349.
|
|
[27] KAMISAWA T, WOOD LD, ITOI T, et al. Pancreatic cancer[J]. Lancet, 2016, 388(10039):73-85.
|
|
[28] QIAN ZR, RUBINSON DA, NOWAK JA, et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma[J]. JAMA Oncol, 2018, 4(3):e173420.
|
|
[29] KANDA M, MATTHAEI H, WU J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia[J]. Gastroenterology, 2012, 142(4):730-733.
|
|
[30] ARDITO CM, GRÜNER BM, TAKEUCHI KK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis[J]. Cancer Cell, 2012, 22(3):304-317.
|
|
[31] HALFDANARSON TR, FOSTER NR, KIM GP, et al. A phaseⅡrandomized trial of panitumumab, erlotinib, and gemcitabine versus erlotinib and gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma:North Central Cancer Treatment Group Trial N064B(Alliance)[J]. Oncologist, 2019, 24(5):589-e160.
|
|
[32] MARON R, SCHECHTER B, NATARAJ NB, et al. Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies[J]. Biochem Biophys Res Commun, 2019, 513(1):219-225.
|
|
[33] BLASCO MT, NAVAS C, MARTÍN-SERRANO G, et al. Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF[J].Cancer Cell, 2019, 35(4):573-587.
|
|
[34] LI Z, WANG M, YAO X, et al. Development of a novel EGFRtargeting antibody-drug conjugate for pancreatic cancer therapy[J]. Target Oncol, 2019, 14(1):93-105.
|
DownLoad: